Indegene Peer Comparison

NSE: INDGN | BSE: 544172

₹593.50

₹2.75 (0.47%)

As on 01-Oct-2026IST

Market cap

₹14,313 Cr

Revenue (TTM)

₹3,813 Cr

P/E Ratio

35.7

P/B Ratio

4.5

Div. Yield

0.4 %

Edit

	Indegene	Sai Life Sciences	Marksans Pharma	Sanofi Consumer Healthcare India	Dishman Carbogen
Market cap (₹ Cr)	14,313	32,710	14,737	8,704	2,364
Revenue (₹ Cr)	3,813	2,250	3,172	950	2,901
Net Profit (₹ Cr)	400.90	361.74	521.27	266.00	16.16
Net Margin (%)	10.30	15.77	15.92	27.44	0.55
RoE (%)	13.87	15.47	18.10	72.69	0.29
Price to Earnings	35.70	90.42	28.52	32.72	146.26
Price-To-Book	4.46	12.81	4.64	25.02	0.36

Income Statement (₹ Cr)

	Indegene	Sai Life Sciences	Marksans Pharma	Sanofi Consumer Healthcare India	Dishman Carbogen
Operating Revenue	3,510.50	2,192.49	2,950.94	878.40	2,931.90
Total Income	3,582.50	2,266.90	3,033.47	896.80	2,987.84
Total Expenditure	2,891.50	1,584.97	2,350.16	569.40	2,366.27
EBITDA	619.00	607.53	600.78	309.00	565.63
Depreciation	126.40	166.86	98.63	11.70	338.69
EBIT	492.60	440.67	502.15	297.30	226.94
Interest	19.30	40.88	24.13	2.00	174.18
Other Income	72.00	74.40	82.53	18.40	55.94
Exceptional Items	-20.30	-8.00	--	6.60	-3.80
Profit before Tax	525.00	466.19	560.56	320.30	104.90
Provision for Tax	123.90	117.28	140.49	80.20	7.45
Profit after Tax	401.10	348.91	420.06	240.10	97.45

	Indegene	Sai Life Sciences	Marksans Pharma	Sanofi Consumer Healthcare India	Dishman Carbogen
Shareholder's Funds	3,138.70	2,483.69	3,023.16	384.00	6,676.90
Minority Interest	--	--	29.52	--	--
Non-Current Liabilities	318.60	321.65	268.17	229.90	2,846.00
Current Liabilities	1,086.20	904.59	527.09	128.40	2,317.05
Total Liabilities	4,620.30	3,709.93	3,855.82	750.80	11,911.40

	Indegene	Sai Life Sciences	Marksans Pharma	Sanofi Consumer Healthcare India	Dishman Carbogen
Non-Current Assets	1,925.10	2,228.49	1,125.20	248.00	8,997.85
Current Assets	2,618.40	1,481.44	2,722.74	494.30	2,842.10
Total Assets	4,620.30	3,709.93	3,855.82	750.80	11,911.40
Total Debt*	0.00	95.13	29.59	0.00	2,775.40
Net Current Assets	1,532.20	576.85	2,195.65	365.90	525.05
Contingent Liabilities	--	97.31	--	1.50	428.74

	Indegene	Sai Life Sciences	Marksans Pharma	Sanofi Consumer Healthcare India	Dishman Carbogen
Cash From Operating Activities	650.80	509.13	458.13	174.80	491.45
Cash Flow from Investing Activities	-512.40	-395.41	-248.27	7.60	-245.34
Cash from Financing Activities	-82.60	-123.68	-70.93	-134.50	200.58
Net Cash Inflow / Outflow	55.80	-9.96	138.93	47.90	446.69

	Indegene	Sai Life Sciences	Marksans Pharma	Sanofi Consumer Healthcare India	Dishman Carbogen
ROCE (%)	18.92	20.97	21.10	98.11	3.21
ROE (%)	14.14	15.16	15.31	73.20	1.56
ROA (%)	10.31	10.09	11.85	37.26	0.89
EBIT Margin (%)	19.68	31.10	23.16	37.27	21.20
Net Margin (%)	11.20	15.39	13.85	26.77	3.26
Cash Profit Margin (%)	15.03	23.50	17.07	27.35	14.88

	Indegene	Sai Life Sciences	Marksans Pharma	Sanofi Consumer Healthcare India	Dishman Carbogen
Revenue Growth (%)	23.64	29.38	12.51	21.24	8.13
EBIT Growth (%)	7.72	53.37	14.07	15.44	26.69
Net Profit Growth (%)	-1.38	105.08	9.79	32.65	2,907.72
EPS Growth (%)	-1.79	101.82	9.81	32.65	2,908.18
Book Value Growth (%)	19.89	16.76	22.41	41.18	14.50

	Indegene	Sai Life Sciences	Marksans Pharma	Sanofi Consumer Healthcare India	Dishman Carbogen
Price / Earnings	26.06	58.91	17.04	43.36	20.92
Price / Book Value	3.38	8.29	2.36	27.11	0.31
Dividend Yield (%)	0.52	0.00	0.57	1.66	0.00
EV/EBITDA	14.57	30.12	9.02	30.65	6.15
Market Cap (₹ Cr)	10,450.76	20,554.39	7,121.50	10,410.62	2,038.26

	Indegene	Sai Life Sciences	Marksans Pharma	Sanofi Consumer Healthcare India	Dishman Carbogen
Debt to Equity	0.00	0.04	0.01	0.00	0.42
Short term debt to equity ratio	--	0.03	0.01	--	0.13
Current Ratio	2.41	1.64	5.17	3.85	1.23
Quick Ratio	2.41	1.47	3.32	3.37	0.79
Interest Coverage	28.20	12.40	24.24	161.15	1.60

	Indegene	Sai Life Sciences	Marksans Pharma	Sanofi Consumer Healthcare India	Dishman Carbogen
Debtors to sales (%)	27.97	17.04	21.84	3.37	22.95
Asset Turnover	0.90	0.63	0.86	1.43	0.27
Receivable days	90.10	60.56	71.16	8.58	83.29
Inventory Days	0.00	22.43	109.20	20.38	119.47
Payable days	--	194.31	91.82	118.89	197.26
Cash Conversion Cycle	--	-111.32	88.55	-89.93	5.50

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.